With the investment Kiox will finalise product development on KX01 before moving into clinical trials. We have further strengthened our pipeline with another inhaled therapy (KX03) that now enters pre-clinical development.
Kiox is accepted into the Innobooster program by Innovation Fund Denmark. The grant will fund development of a new treatments for interstitial lung disases.
Iconovo is a leading inhalation formulation and device company based in Lund, Sweden. Kiox andIconovo will work on developing inhaled treatment for rare lung diseases.
Receive quarterly news about Kiox